Limited Offer: Save €100 Today - Use Code: JKL70G
Medication

Ozempic or Mounjaro? Here is what you need to know

Discover the key differences in how these popular weight loss methods work and how effective they are, and find out which option is the best fit for you.

What is the difference between Mounjaro and Ozempic?

Mounjaro and Ozempic are both once-weekly medications that aid in weight loss, but they differ in significant ways: from their active ingredients and mechanisms of action to their efficacy and availability. On the surface, these two medications share many similarities. Both work hormonally, suppress appetite, and are administered subcutaneously. However, they are fundamentally different drugs, each with its own mechanism of action and profile. This blog explains the differences in detail so you can make an informed choice with Goodweigh.

What is the difference in active ingredients?

The main difference between these two medications lies in their active ingredients. Ozempic contains semaglutide, which is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced by the gut after a meal. It suppresses appetite, slows gastric emptying, and stimulates insulin release. Semaglutide mimics this hormone, thereby enhancing the feeling of fullness.

Mounjaro contains tirzepatide and acts on two hormonal systems simultaneously: it activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that also plays a role in fat storage, appetite, and energy regulation. By activating both systems at the same time, Mounjaro has a broader and often more potent effect on metabolism than Ozempic.

What were these medications developed for?

Both medications were originally developed to treat type 2 diabetes. Ozempic is officially registered in the Netherlands for the treatment of diabetes, but in practice, it is also used for weight loss outside of its official indication, which is known as "off-label" use. Weight loss emerged as a side effect in clinical trials, after which doctors began using the medication increasingly for overweight patients.

Mounjaro followed the same pattern: it was primarily developed to treat type 2 diabetes but has since been approved in several countries for the treatment of obesity as well.

How do Mounjaro and Ozempic differ in terms of efficacy?

The difference in their mechanisms of action is clearly reflected in measurable results in clinical practice. According to a study published in the New England Journal of Medicine, participants without diabetes lost an average of the following after 72 weeks:

  • 20.2% of their body weight with tirzepatide (Mounjaro)
  • 13.7% of body weight with semaglutide (Ozempic)

This is a direct head-to-head comparison at the same maximum tolerated dose. A large-scale real-world study also confirms this picture: a study, in which over 40,000 people met the study criteria, shows that people using tirzepatide lost weight significantly more often than those using semaglutide.

Despite this, results depend heavily on individual factors such as lifestyle, treatment adherence, starting weight, and any underlying health conditions. Mounjaro and Ozempic can be introduced in the Goodweigh program if medically appropriate, always in conjunction with a personalized coaching program.

What is the difference in dosage and dose escalation?

Both medications are administered once a week as a subcutaneous injection into the abdomen, thigh, or upper arm. Ozempic treatment starts with a 0.25 mg dose of semaglutide per week and can be increased in stages to 1.0 or 2.0 mg, depending on the product used and the medical indication.

Mounjaro is started at a 2.5 mg dose of tirzepatide per week, and the dose is increased in 2.5 mg increments up to a maximum of 15 mg. Mounjaro's dose escalation steps are larger, and the pen sizes differ from those of Ozempic. Each pen contains a single fixed dose that cannot be adjusted manually. Both treatment paths always proceed under medical supervision so that the dosage can be adapted to the patient's response and tolerability.

‍

Which medication is better tolerated, and is there a difference in side effects?

The side effects of Mounjaro and Ozempic are largely similar. The most common mild symptoms include nausea, vomiting, diarrhea, and a feeling of fullness in the stomach, especially during the first weeks of treatment or after a dose increase. These are typical effects of GLP-1 activation and subside on their own for most people as the body adjusts to the medication. Regarding serious side effects: according to a comparative study , the total number of people who experienced side effects was comparable in both groups, but serious side effects occurred slightly more frequently with tirzepatide than with semaglutide

Which medication is better tolerated varies greatly from person to person. Some experience more symptoms with Mounjaro during the dose escalation phase due to the larger dose steps; others tolerate it better than semaglutide. Goodweigh takes this into account in the medical assessment: if you are sensitive to side effects, this is considered when choosing the starting medication and the speed of dose escalation.

‍

What is right for your situation?

Ozempic is a proven, widely available medication with a comprehensive safety profile and years of clinical experience. It is an excellent first-line choice for people starting medication to support weight loss. Mounjaro is a newer medication with a more potent dual-action mechanism. In clinical trials, it has led to greater average weight loss, making it an attractive option for people who want a stronger effect or for whom Ozempic did not produce sufficient results.

However, the best choice is always personal. Factors such as your health status, any other medications you may be taking, your experience with side effects, and your personal preferences all influence the decision. Goodweigh helps you make an informed choice based on an initial assessment and a medical evaluation.

Together with Goodweigh, you will choose the medication that is just right for you

You don't have to figure it out on your own. Goodweigh guides you step-by-step through the selection of different weight-loss medications, all tailored to your specific goals, health status, and preferences. A doctor will evaluate your situation and create a personalized treatment plan. This way, you can start with confidence, knowing what to expect and that you are not alone. Online assessment.

Viitteet

  • Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W. Y., ... & Jastreboff, A. M. (2025). Tirzepatide versus semaglutide for the treatment of obesity. New England Journal of Medicine, 392(22), 2031–2044. https://pubmed.ncbi.nlm.nih.gov/40353578/
  • Brit Long, Jessica Pelletier, Alex Koyfman, Rachel E. Bridwell, GLP-1 agonists: A review for emergency physicians, The American Journal of Emergency Medicine, Volume 78, 2024, pages 89–94, ISSN 0735-6757, https://doi.org/10.1016/j.ajem.2024.01.010.
  • Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022). Tirzepatide, a new era in the dual-targeted treatment of diabetes and obesity: A brief review. Molecules, 27(13), 4315. https://doi.org/10.3390/molecules27134315
  • Mounjaro. (n.d.). Mounjaro. A Lilly Medicine. Mounjaro.lilly. Retrieved March 19, 2026, from https://mounjaro.lilly.com/
  • Ozempic. (n.p.). Ozempic. Ozempic.com. Retrieved March 19, 2026, from https://www.ozempic.com/
  • Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine, 184(9), 1056–1064. https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/